GOAL: The goal of this study was to investigate the potential role of clinical and electrophysiological signs of chemotherapy-induced neurotoxicity (CIPN) in predicting the final outcome of CIPN. PATIENTS AND METHODS: We prospectively studied 46 cancer patients treated with paclitaxel, cisplatin, or their combination-containing regimens for a nonmyeloid malignancy. The clinical evaluation of neuropathy was based on the modified Neurological Symptom and Neurological Disability Scores. Neurophysiological examination was also carried out. The battery of clinical and electrophysiological tests was repeated at the third and sixth courses of chemotherapy and up to 3 months after its cessation. Results of the clinical and electrophysiological study were summarized by means of a modified peripheral neuropathy (PNP) score. RESULTS: Patients were divided according to the PNP scores obtained at follow-ups into those with better outcome (group 1, PNP <14, n=19) and those with worse outcome (group 2, PNP >15, n=27). In each patient and before the maximum severity of CIPN had been reached, the incidence of clinical and electrophysiological variables was determined and compared between groups. After univariate analysis two variables from the clinical evaluation and one from the neurophysiological evaluation were related to higher severity of CIPN and thus with worse outcome. Multivariate regression analysis defined only one of them, namely, the decrease sural a-SAP >50% of the baseline value, as being the sole, significant predictor of worse neurological outcome. CONCLUSION: Our study indicates that a precise clinical evaluation combined with a detailed electrophysiological evaluation could predict the final neurological outcome of the cisplatin- or/and paclitaxel-based chemotherapy.
GOAL: The goal of this study was to investigate the potential role of clinical and electrophysiological signs of chemotherapy-induced neurotoxicity (CIPN) in predicting the final outcome of CIPN. PATIENTS AND METHODS: We prospectively studied 46 cancerpatients treated with paclitaxel, cisplatin, or their combination-containing regimens for a nonmyeloid malignancy. The clinical evaluation of neuropathy was based on the modified Neurological Symptom and Neurological Disability Scores. Neurophysiological examination was also carried out. The battery of clinical and electrophysiological tests was repeated at the third and sixth courses of chemotherapy and up to 3 months after its cessation. Results of the clinical and electrophysiological study were summarized by means of a modified peripheral neuropathy (PNP) score. RESULTS:Patients were divided according to the PNP scores obtained at follow-ups into those with better outcome (group 1, PNP <14, n=19) and those with worse outcome (group 2, PNP >15, n=27). In each patient and before the maximum severity of CIPN had been reached, the incidence of clinical and electrophysiological variables was determined and compared between groups. After univariate analysis two variables from the clinical evaluation and one from the neurophysiological evaluation were related to higher severity of CIPN and thus with worse outcome. Multivariate regression analysis defined only one of them, namely, the decrease sural a-SAP >50% of the baseline value, as being the sole, significant predictor of worse neurological outcome. CONCLUSION: Our study indicates that a precise clinical evaluation combined with a detailed electrophysiological evaluation could predict the final neurological outcome of the cisplatin- or/and paclitaxel-based chemotherapy.
Authors: B G McCarthy; S T Hsieh; A Stocks; P Hauer; C Macko; D R Cornblath; J W Griffin; J C McArthur Journal: Neurology Date: 1995-10 Impact factor: 9.910
Authors: G Cavaletti; G Bogliun; L Marzorati; A Zincone; M Piatti; N Colombo; D Franchi; M T La Presa; A Lissoni; A Buda; F Fei; S Cundari; C Zanna Journal: Ann Oncol Date: 2004-09 Impact factor: 32.976
Authors: Dana M Chase; James Kauderer; Lari Wenzel; Lois Ramondetta; David Cella; Harry J Long; Bradley J Monk Journal: Int J Gynecol Cancer Date: 2015-02 Impact factor: 3.437
Authors: Kathleen A Griffith; Shijun Zhu; Meg Johantgen; Michael D Kessler; Cynthia Renn; Andreas S Beutler; Rahul Kanwar; Nicholas Ambulos; Guido Cavaletti; Jordi Bruna; Chiara Briani; Andreas A Argyriou; Haralabos P Kalofonos; Laura M Yerges-Armstrong; Susan G Dorsey Journal: J Pain Symptom Manage Date: 2017-07-23 Impact factor: 3.612
Authors: Andreas A Argyriou; Panagiotis Polychronopoulos; Angelos Koutras; Gregoris Iconomou; Philippos Gourzis; Konstantinos Assimakopoulos; Haralabos P Kalofonos; Elisabeth Chroni Journal: Support Care Cancer Date: 2005-07-15 Impact factor: 3.603
Authors: Kathleen A Griffith; Susan G Dorsey; Cynthia L Renn; Shijun Zhu; Mary E Johantgen; David R Cornblath; Andreas A Argyriou; Guido Cavaletti; Ingemar S J Merkies; Paola Alberti; Tjeerd J Postma; Emanuela Rossi; Barbara Frigeni; Jordi Bruna; Roser Velasco; Haralabos P Kalofonos; Dimitri Psimaras; Damien Ricard; Andrea Pace; Edvina Galie; Chiara Briani; Chiara Dalla Torre; Catharina G Faber; Roy I Lalisang; Willem Boogerd; Dieta Brandsma; Susanne Koeppen; Joerg Hense; Dawn J Storey; Simon Kerrigan; Angelo Schenone; Sabrina Fabbri; Maria Grazia Valsecchi Journal: J Peripher Nerv Syst Date: 2014-06 Impact factor: 3.494